Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: CLDI )

2.150 -0.140 (-6.11%)
Official Closing Price Updated: 6:30 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CLDI

< Previous 1 2 Next >
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases RTNova Virotherapy Breakthrough for Metastatic Cancer Treatment
Via Investor Brand Network
TechMediaBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering to Support Immunotherapy Development
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Is ‘One to Watch’
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Groundbreaking Cancer Treatment on RedChip’s Bloomberg TV Program
Via Investor Brand Network
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Antitumor Virotherapy Platform Data at Three Scientific Conferences
Via Investor Brand Network
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member
Via Investor Brand Network
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi 
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Calidi to Effect Reverse Stock Split
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Calidi Biotherapeutics, Inc.
Via Business Wire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV
Via ACCESSWIRE
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
From Calidi Biotherapeutics, Inc.
Via Business Wire
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
From Calidi Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.